Administration_of_interleukin-2_(IL-2)_results_in_increased_plasma_concentrations_of_IL-5_and_eosinophilia_in_patients_with_cancer._Peripheral_eosinophilia_is_almost_invariably_observed_during_the_course_of_interleukin-2_(IL-2)_therapy_and_is_frequently_accompanied_by_the_development_of_a_capillary_leak_syndrome_characterized_by_edema,_weight_gain,_and_oliguria._We_studied_five_patients_with_advanced_malignancy_treated_with_IL-2._Eosinophilia_was_not_present_initially_but_developed_in_all_patients_late_in_the_course_of_therapy,_with_counts_ranging_from_2,328/mm3_to_15,958/mm3._In_all_patients,_there_was_a_temporal_relationship_between_the_infusion_of_IL-2_and_the_appearance_of_elevated_plasma_concentrations_of_IL-5,_a_growth_factor_for_eosinophils._Granulocyte-macrophage_colony-stimulating_factor_was_not_detectable_in_plasma._IL-4_and_gamma-interferon_plasma_levels_were_variably_elevated._Plasma_concentrations_of_major_basic_protein,_a_toxic_eosinophil_granule_protein,_began_increasing_before_eosinophil_counts_increased._By_the_time_of_the_third_IL-2_infusion,_high_concentrations_of_major_basic_protein_were_present_in_all_five_patients_(up_to_5,600_ng/mL)_and_skin_biopsies_showed_major_basic_protein_deposition_in_the_dermis._Four_patients_developed_significant_capillary_leak_syndrome_and_all_of_these_patients_showed_markedly_elevated_major_basic_protein_levels._The_lowest_peak_plasma_concentration_of_major_basic_protein_(1,751_ng/mL)_was_observed_in_the_one_patient_who_did_not_develop_edema_and_weight_gain._These_results_suggest_that_IL-2_induces_IL-5_leading_to_marked_peripheral_eosinophilia_and_extravascular_eosinophil_degranulation._The_release_of_toxic_eosinophil_products_at_extravascular_sites_and_in_the_circulation_may_contribute_to_the_pathogenesis_of_the_capillary_leak_syndrome_complicating_IL-2_therapy.